NEWS

María José Sánchez Losada, new president of AELMHU

María José Sánchez Losada, new president of AELMHU

María José Sánchez Losada has been appointed president of the Spanish Association of Orphan and Ultra Orphan Drug Laboratories (AELMHU), replacing Jorge Capapey, who will remain on the board as vice-president, alongside Leticia Beleta and David Moreno.

María José has been Managing Director of CSL Behring Iberia for the last 4 years and has an extensive experience in the pharmaceutical industry, where she has held different responsibilities at local and global level.

Since 2020, he is a member of the Board of AELMHU, which guarantees the continuation of the project initiated by the Board chaired by Capapey in June last year and whose priority is to ensure rapid and equitable access to orphan therapies for all patients in Spain.

The AELMHU Board of Directors, now headed by María José Sánchez, will maintain its current structure of three vice-presidencies led by Leticia Beleta, General Manager of Alexion AstraZeneca Rare Disease in Spain, David Moreno, General Manager of PTC Therapeutics in Spain and Jorge Capapey VP, Head of Commercial CEMEA at Alnylam.